Skip to main content

Table 1 SUCCESS patient characteristics before and after chemotherapy for EFC#93 serum DNAme

From: Methylation patterns in serum DNA for early identification of disseminated breast cancer

Characteristic Before chemotherapy After chemotherapy
EFC#93– (%) EFC#93+ (%) P valuea EFC#93– (%) EFC#93+ (%) P valuea
Patients (n) 385 (91.9) 34 (8.1)   371 (89.4) 44 (10.6)  
Age (mean ± SD) 53.7 ± 10.3 55.2 ± 10.1 0.380 53.5 ± 10.4 56.2 ± 9.3 0.097
Menopausal status Premenopausal 165 (42.9) 15 (44.1) 1.000 165 (44.5) 15 (34.1) 0.202
Postmenopausal 220 (57.1) 19 (55.9)   206 (55.5) 29 (65.9)  
Stage (T) T1 158 (41.0) 9 (26.5) 0.110 157 (42.3) 10 (22.7) 0.014
T2–4 227 (59.0) 25 (73.5)   214 (57.7) 34 (77.3)  
Nodes (N) NO 130 (33.9) 7 (20.6) 0.130 124 (33.4) 13 (30.2) 0.735
N1–3 254 (66.1) 27 (79.4)   247 (66.6) 30 (69.8)  
Histology Invasive ductal 310 (80.5) 25 (73.5) 0.370 296 (79.8) 36 (81.8) 0.844
Others 75 (19.5) 9 (26.5)   75 (20.2) 8 (18.2)  
Grading Grade 1/2 199 (51.7) 16 (47.1) 0.721 190 (51.2) 23 (52.3) 1.000
Grade 3 186 (48.3) 18 (52.9)   181 (48.8) 21 (47.7)  
Estrogen (ER) receptor ER– 128 (33.2) 10 (29.4) 0.708 128 (34.5) 10 (22.7) 0.130
ER+ 257 (66.8) 24 (70.6)   243 (65.5) 34 (77.3)  
Progesterone (PR) receptor PR– 155 (40.4) 11 (32.4) 0.465 150 (40,5) 16 (36.4) 0.629
PR+ 229 (59.6) 23 (67.6)   220 (59.5) 28 (63.6)  
HER2 status HER2– 294 (77.0) 24 (70.6) 0.403 276 (75.0) 38 (86.4) 0.132
HER2+ 88 (23.0) 10 (29.4)   92 (25.0) 6 (13.6)  
Surgery Breast conserving 273 (70.9) 16 (47.1) 0.006 264 (71.2) 23 (52.3) 0.015
Mastectomy 112 (29.1) 18 (52.9)   107 (28.8) 21 (47.7)  
Chemotherapy FEC-D 193 (50.1) 18 (52.9) 0.858 186 (50.1) 22 (50.0) 1.000
FEC-DG 192 (49.9) 16 (47.1)   185 (49.9) 22 (50.0)  
Bisphosphonates Zometa 2 years 193 (50.1) 17 (50.0) 1.000 185 (49.9) 23 (52.3) 0.874
Zometa 5 years 192 (49.9) 17 (50.0)   186 (50.1) 21 (47.7)  
Circulating tumor cells (CTCs) CTC– before chemo 316 (82.1) 20 (58.8) 0.003 303 (81.7) 32 (72.3) 0.160
CTC+ before chemo 69 (17.9) 14 (41.2)   68 (18.3) 12 (27.7)  
CTC– after chemo 304 (79.0) 27 (79.4) 1.000 302 (81.4) 28 (63.6) 0.009
CTC+ after chemo 81 (21.0) 7 (20.6)   69 (18.6) 16 (36.4)  
  1. EFC#93 serum DNAme was deemed positive (+ve) at or above a pattern frequency of 0.00008
  2. aTwo-sided t-test (contingent upon age) or Chi-square test (for all other parameters)
  3. Information on N, PR and HER2 is missing from 1, 1 and 3 patients, respectively. Serum DNAme was not analysed for 4 post-treatment samples
  4. FEC-D fluorouracil-epirubicin-cyclophosphamide (500/100/500 mg/m2, FEC) followed by docetaxel (100 mg/mg2), FEC-DG fluorouracil-epirubicin-cyclophosphamide (500/100/500 mg/m2, FEC) followed by gemcitabine (1000 mg/m2 d1,8)-docetaxel (75 mg/m2), SD standard deviation